• Policy
• What's Kymriah's procedure after passing the Committee?
• by Lee, Hye-Kyung Oct 19, 2021 08:54pm

• Policy
• The benefit of 7 α-GPC products will be suspended
• by Lee, Hye-Kyung Oct 19, 2021 08:53pm

• Company
• Hugel’s Geodu BTX plant completes EMA inspection
• by Lee, Seok-Jun Oct 19, 2021 06:00am

• Policy
• Korea United Pharm's Galvusmet generic is the first approved
• by Lee, Tak-Sun Oct 19, 2021 06:00am

• Company
• Hugel's Letybo benefits from FDA delay of Revance's DAXI
• by Nho, Byung Chul Oct 18, 2021 05:54am

• Company
• Novartis applies for another gene therapy, Luxturna
• by Eo, Yun-Ho Oct 18, 2021 05:54am

• Policy
• Keytruda·Tagrisso is in the process of expanding benefits
• by Lee, Hye-Kyung Oct 18, 2021 05:54am

• Policy
• “Impartiality of reimbursement review system undermined"
• by Lee, Jeong-Hwan Oct 18, 2021 05:54am

• Policy
• Introduction of CDF for Zolgensma was proposed
• by Lee, Hye-Kyung Oct 18, 2021 05:54am

• Company
• Bayer·Viatris·Pfizer settles in new locations
• by Eo, Yun-Ho Oct 18, 2021 05:54am